更多开发者作品
The Lancet Infectious Diseases
| 1. | [Comment] Difficulties in diagnosing tuberculosis infection in childhood | Anna Starshinova | |
| 2. | [Media Watch] Globalisation and COVID-19 | Matilda Lawson | |
| 3. | [Corrections] Correction to Lancet Infect Dis 2024; published online Sept 10. https://doi.org/10.1016/S1473-3099(24)00585-1 | | |
| 4. | [Articles] Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study | Laura Olbrich, Zoe Franckling-Smith, Leyla Larsson, Issa Sabi, Nyanda Elias Ntinginya, Celso Khosa, Denise Banze, Marriott Nliwasa, Elizabeth Lucy Corbett, Robina Semphere, Valsan Philip Verghese, Joy Sarojini Michael, Marilyn Mary Ninan, Elmar Saathoff, Timothy Daniel McHugh, Alia Razid, Stephen Michael Graham, Rinn Song, Pamela Nabeta, Andre Trollip, Mark Patrick Nicol, Michael Hoelscher, Christof Geldmacher, Norbert Heinrich, Heather Joy Zar, RaPaed-AIDA-TB consortium | |
| 5. | [Correspondence] Financing infectious disease services in hospitals: a common public good | Joseph D Tucker | |
| 6. | [Media Watch] Vaccine hesitancy in Scandinavia | Hollie Sherwood-Martin | |
| 7. | [Articles] Mosquito-disseminated pyriproxyfen for mosquito-borne disease control in Belo Horizonte, Brazil: a pragmatic, before–after control–intervention paired-series trial | Fernando Abad-Franch, José Joaquín Carvajal-Cortés, Ana Carolina Lemos Rabelo, Eduardo Viana Vieira Gusmão, Samylla Suany de Souza Soares, Sérgio Luiz Bessa Luz | |
| 8. | [Comment] Quantifying the effect of vector targeted interventions to control dengue | Henrik Salje | |
| 9. | [Articles] Temporary adaptations to sexual behaviour during the mpox outbreak in 23 countries in Europe and the Americas: findings from a retrospective cross-sectional online survey | Mateo Prochazka, Pietro Vinti, Ana Hoxha, Andy Seale, Antons Mozalevskis, Rosamund Lewis, Ruben Mayorga Sagastume, Martha Scherzer, Leilia Dore, Meg Doherty | |
| 10. | [Personal View] Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings | Richard Kwizera, Alireza Abdolrasouli, Guillermo Garcia-Effron, David W Denning | |
| 11. | [Comment] Mpox control strategies: using behaviour change to complement, not replace, vaccination | Marc C Shamier, Kai J Jonas | |
| 12. | [Newsdesk] Polio vaccination campaign in Gaza | Talha Burki | |
| 13. | [Articles] Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study | Timothy W Russell, Hermaleigh Townsley, Joel Hellewell, Joshua Gahir, Marianne Shawe-Taylor, David Greenwood, David Hodgson, Agnieszka Hobbs, Giulia Dowgier, Rebecca Penn, Theo Sanderson, Phoebe Stevenson-Leggett, James Bazire, Ruth Harvey, Ashley S Fowler, Murad Miah, Callie Smith, Mauro Miranda, Philip Bawumia, Harriet V Mears, Lorin Adams, Emine Hatipoglu, Nicola O'Reilly, Scott Warchal, Karen Ambrose, Amy Strange, Gavin Kelly, Svend Kjar, Padmasayee Papineni, Tumena Corrah, Richard Gilson, Vincenzo Libri, George Kassiotis, Steve Gamblin, Nicola S Lewis, Bryan Williams, Charles Swanton, Sonia Gandhi, Rupert Beale, Mary Y Wu, David L V Bauer, Edward J Carr, Emma C Wall, Adam J Kucharski | |
| 14. | [Comment] Kinetics of neutralising antibodies against SARS-CoV-2 variants | Piero Poletti | |
| 15. | [Correspondence] ArboTracker: a multipathogen dashboard and data platform for arbovirus seroprevalence studies | Mairead G Whelan, Harriet Ware, Himanshu Ranka, Sean Kenny, Sabah Shaikh, Yannik Roell, Shaila Akter, Anabel Selemon, Emilie Toews, May Chu, Niklas Bobrovitz, Rahul K Arora, Thomas Jaenisch | |
| 16. | [Comment] The worsening mpox outbreak in Africa: a call to action | Krutika Kuppalli, Jake Dunning, Inger Damon, Daniel Mukadi-Bamuleka, Placide Mbala, Dimie Ogoina | |
| 17. | [Correspondence] Mpox outbreak—tecovirimat resistance, management approaches, and challenges in HIV-endemic regions | Wyvine Ansima Bapolisi, Susanne Krasemann, Misaki Wayengera, Bruce Kirenga, Esto Bahizire, Espoir Bwenge Malembaka, Joseph Nelson Siewe Fodjo, Robert Colebunders, Patrick DMC Katoto | |
| 18. | [Articles] Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021 | GBD 2021 Upper Respiratory Infections Otitis Media Collaborators | |
| 19. | [Comment] SARS-CoV-2 antivirals and post-COVID-19 condition | Ziyad Al-Aly | |
| 20. | [Articles] Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial | Victoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, Najib M Rahman, Duncan B Richards, Gail Hayward, Jienchi Dorward, David M Lowe, Joseph F Standing, Judith Breuer, Saye Khoo, Stavros Petrou, Kerenza Hood, Haroon Ahmed, Andrew Carson-Stevens, Jonathan S Nguyen-Van-Tam, Mahendra G Patel, Benjamin R Saville, Nick Francis, Nicholas P B Thomas, Philip Evans, Melissa Dobson, May Ee Png, Mark Lown, Oliver van Hecke, Bhautesh D Jani, Nigel D Hart, Daniel Butler, Lucy Cureton, Meena Patil, Monique Andersson, Maria Coates, Clare Bateman, Jennifer C Davies, Ivy Raymundo-Wood, Andrew Ustianowski, Ly-Mee Yu, F D Richard Hobbs, Paul Little, Christopher C Butler, PANORAMIC Trial Collaborative Group | |
| 21. | [Comment] Burden of upper respiratory infections and otitis media | Tal Marom | |
| 22. | [Correspondence] Potential vertical transmission of Oropouche virus during the current outbreak | Athina Samara, Conrado Milani Coutinho, Philip Veal, Jane Osborne, Geraldo Duarte, Shamez Ladhani, Asma Khalil | |
| 23. | [Newsdesk] Mpox emergency in Africa | Esther Nakkazi | |
| 24. | [Comment] Next-generation influenza vaccines based on mRNA technology | Irina Isakova-Sivak, Larisa Rudenko | |
| 25. | [Articles] Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50–75 years: a phase 1/2, open-label, randomised trial | Denise Hsu, Akila Jayaraman, Alicia Pucci, Riya Joshi, Kevin Mancini, Hui Ling Chen, Kindra Koslovsky, Xuezhou Mao, Angela Choi, Carole Henry, Jignesh Vakil, Daniel Stadlbauer, Patricia Jorquera, Guha Asthagiri Arunkumar, Nelia E Sanchez-Crespo, L Tyler Wadsworth, Vellore Bhupathy, Evelyn Du, Andrei Avanesov, Jintanat Ananworanich, Raffael Nachbagauer | |
| 26. | [Articles] The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: an umbrella review | Suzanne M E Kuijpers, David T P Buis, Kirsten A Ziesemer, Reinier M van Hest, Rogier P Schade, Kim C E Sigaloff, Jan M Prins | |
| 27. | [Articles] Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents | Vera Buerger, Sandra Hadl, Martina Schneider, Michaela Schaden, Romana Hochreiter, Annegret Bitzer, Karin Kosulin, Robert Mader, Oliver Zoihsl, Andrea Pfeiffer, Ana Paula Loch, Eolo Morandi, Mauricio Lacerda Nogueira, Carlos Alexandre Antunes de Brito, Julio Croda, Mauro Martins Teixeira, Ivo Castelo-Branco Coelho, Ricardo Gurgel, Allex Jardim da Fonseca, Marcus Vinícius Guimarães de Lacerda, Edson Duarte Moreira, Ana Paula Rocha Veiga, Katrin Dubischar, Nina Wressnigg, Susanne Eder-Lingelbach, Juan Carlos Jaramillo | |
| 28. | [Comment] First immunogenicity and safety data on live chikungunya vaccine in an endemic area | David O Freedman, Annika Beate Wilder-Smith, Annelies Wilder-Smith | |
| 29. | [Comment] Shorter antibiotic courses for respiratory tract infections | Javeria Tariq, Ritu Banerjee | |
| 30. | [Articles] Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial | Flonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, Jennifer D Hamilton, Benjamin A Olenchock, Taylor Brackin, Samit Ganguly, Eduardo Forleo-Neto, Lori Faria, Ingeborg Heirman, Mary Marovich, Julia Hutter, Laura Polakowski, Susan C Irvin, Mazhar Thakur, Andrea T Hooper, Alina Baum, Christopher D Petro, Faisal A Fakih, M Juliana McElrath, Stephen C De Rosa, Kristen W Cohen, LaTonya D Williams, Caleb A Hellman, Ahmad J Odeh, Aloki H Patel, Georgia D Tomaras, Gregory P Geba, Christos A Kyratsous, Bret Musser, George D Yancopoulos, Gary A Herman, Trial Working Group | |
| 31. | [Correspondence] Limitations of mpox lateral flow tests in assessing orthopoxvirus immunity | Toby Jones, Scott Jones, Bethany Hicks, Hannah Selman, Cathy Rowe, Ashley D Otter | |
| 32. | [Comment] Weighing up monoclonals and vaccination against COVID-19 | David L V Bauer | |
| 33. | [Media Watch] Facing COVID-19 in South Africa | Jonathan Blott | |
| 34. | [Correspondence] Mpox—is there a more dangerous new clade? | Christian Hoffmann | |
| 35. | [Media Watch] Biopolitical precarity for women with HIV in South Africa | Emma Starbuck | |
| 36. | [Media Watch] Antiblackness in the Ebola response in Sierra Leone | Elizabeth Haslam | |
| 37. | [Corrections] Correction to Lancet Infect Dis 2024; published online Aug 12. https://doi.org/10.1016/S1473-3099(24)00357-8 | | |
| 38. | [Correspondence] Oropouche virus genomic surveillance in Brazil | Filipe Romero Rebello Moreira, João Victor Rodrigues Dutra, André Henrique Barbosa de Carvalho, Clarisse Rezende Reis, Jéssica Silqueira Hickson Rios, Marisa de Oliveira Ribeiro, Monica Barcellos Arruda, Patricia Alvarez, Renan Pedra Souza, Carolina Voloch, Danielle Alves Gomes Zauli, Renato Santana Aguiar | |
| 39. | [Correspondence] Oropouche fever: reports of vertical transmission and deaths in Brazil | Paulo Ricardo Martins-Filho, Thialla Andrade Carvalho, Cliomar Alves dos Santos | |
| 40. | [Correspondence] Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south | Dhammika Leshan Wannigama, Mohan Amarasiri, Phatthranit Phattharapornjaroen, Cameron Hurst, Charin Modchang, John Jefferson V Besa, Kazuhiko Miyanaga, Longzhu Cui, Stefan Fernandez, Angkana T Huang, Puey Ounjai, Pathogen Hunters Research Team, Andrew C Singer, Naveen Kumar Devanga Ragupathi, Takashi Furukawa, Kazunari Sei, Asuka Nanbo, Asada Leelahavanichkul, Talerngsak Kanjanabuch, Tanittha Chatsuwan, Paul G Higgins, Daisuke Sano, Anthony Kicic, Jürgen Kurt Rockstroh, Richard Siow, Sam Trowsdale, Parichart Hongsing, Aisha Khatib, Kenji Shibuya, Shuichi Abe | |
| 41. | [Comment] Re-evaluating polio vaccination strategies in Nepal: transitioning from OPV to fIPV for sustained immunity | Bhuvan Saud, Saroj Adhikari | |
| 42. | [Correspondence] Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance | Thibaut Vanbaelen, Sheeba Santhini Manoharan-Basil, Chris Kenyon | |
| 43. | [Comment] Assessing the real-world effectiveness of the rVSV-ZEBOV vaccine | Deborah A Williamson, Emma C Thomson | |
| 44. | [Articles] Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study | Sophie Meakin, Justus Nsio, Anton Camacho, Richard Kitenge, Rebecca M Coulborn, Etienne Gignoux, John Johnson, Esther Sterk, Elisabeth Mukamba Musenga, Stephane Hans Bateyi Mustafa, Epicentre-MSF EVD Working Group, Flavio Finger, Steve Ahuka-Mundeke | |
| 45. | [Correspondence] The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus | Min Du, Min Liu, Ben Niu, Jue Liu | |
| 46. | [Correspondence] Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant | Yu Kaku, Keiya Uriu, Kaho Okumura, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Jumpei Ito, Kei Sato | |
| 47. | [Media Watch] Tuberculosis in the USA in 1935 | Sanjeet Bagcchi | |
| 48. | [Articles] Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance | Deus S Ishengoma, Celine I Mandara, Catherine Bakari, Abebe A Fola, Rashid A Madebe, Misago D Seth, Filbert Francis, Creyton C Buguzi, Ramadhan Moshi, Issa Garimo, Samwel Lazaro, Abdallah Lusasi, Sijenunu Aaron, Frank Chacky, Ally Mohamed, Ritha J A Njau, Jovin Kitau, Charlotte Rasmussen, Jeffrey A Bailey, Jonathan J Juliano, Marian Warsame | |
| 49. | [Media Watch] Understanding outbreak preparedness | Manjulika Das | |
| 50. | [Comment] Resistant malaria parasites gaining momentum in Africa | Eulambius M Mlugu, Arjen M Dondorp, Karen I Barnes | |
| 51. | [Comment] Preconception immunisation to prevent pregnancy-associated malaria | Stephanie K Yanow, Daniel Ferrer Vinals | |
| 52. | [Articles] Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial | Kayvon Modjarrad, Paul T Scott, Melanie McCauley, Brittany Ober-Shepherd, Erica Sondergaard, Mihret F Amare, Ajay P Parikh, Badryah Omar, Ada-Marie Minutello, Haritha Adhikarla, Yukun Wu, Andrey Rojas P, Valentine Delore, Nathalie Mantel, Meshell N Morrison, Kamila S Kourbanova, Melissa E Martinez, Ivelese Guzman, Melissa E Greenleaf, Janice M Darden, Michael A Koren, Melinda J Hamer, Christine E Lee, Jack N Hutter, Sheila A Peel, Merlin L Robb, Manuel Vangelisti, Emmanuel Feroldi | |
| 53. | [Comment] The promising prospects of a new yellow fever vaccine | Anna H E Roukens, Leo G Visser | |
| 54. | [Articles] Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials | Halimatou Diawara, Sara A Healy, Agnes Mwakingwe-Omari, Djibrilla Issiaka, Aye Diallo, Seydou Traore, Ibrahim H Soumbounou, Santara Gaoussou, Irfan Zaidi, Almahamoudou Mahamar, Oumar Attaher, Michal Fried, Blair J Wylie, Rathy Mohan, Viyada Doan, Justin Y A Doritchamou, Amagana Dolo, Robert D Morrison, Jing Wang, Zonghui Hu, Kelly M Rausch, Amatigue Zeguime, Tooba Murshedkar, Natasha KC, B Kim Lee Sim, Peter F Billingsley, Thomas L Richie, Stephen L Hoffman, Alassane Dicko, Patrick E Duffy, PfSPZ Vaccine Study Team | |
| 55. | [Articles] Investigating the effect of enhanced cleaning and disinfection of shared medical equipment on health-care-associated infections in Australia (CLEEN): a stepped-wedge, cluster randomised, controlled trial | Katrina Browne, Nicole M White, Philip L Russo, Allen C Cheng, Andrew J Stewardson, Georgia Matterson, Peta E Tehan, Kirsty Graham, Maham Amin, Maria Northcote, Martin Kiernan, Jennie King, David Brain, Brett G Mitchell | |
| 56. | [Articles] Trends in infection incidence and antimicrobial resistance in the US Veterans Affairs Healthcare System: a nationwide retrospective cohort study (2007–22) | Thi Mui Pham, Yue Zhang, McKenna Nevers, Haojia Li, Karim Khader, Yonatan H Grad, Marc Lipsitch, Matthew Samore | |
| 57. | [Comment] Success of the CLEEN study | Dinah Gould, Nicolas Drey | |
| 58. | [Comment] Antibiotic resistance incidence or proportions: where does the greatest burden lie? | Morgan K Walker, Sameer S Kadri | |
| 59. | [Correspondence] Enhancing wastewater testing for H5N1 surveillance | Ranu S Dhillon, Abraar Karan, Devabhaktuni Srikrishna | |
| 60. | [Correspondence] Gonorrhoea and chlamydia screening for asymptomatic people with HIV and HIV PrEP users: open issues | Angelo Roberto Raccagni, Antonella Castagna, Silvia Nozza | |
| 61. | [Articles] Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study | Robert McMahon, Sebastian Toepfer, Natascha Sattler, Martina Schneider, Marivic Narciso-Abraham, Sandra Hadl, Romana Hochreiter, Karin Kosulin, Robert Mader, Oliver Zoihsl, Nina Wressnigg, Katrin Dubischar, Vera Buerger, Susanne Eder-Lingelbach, Juan-Carlos Jaramillo | |
| 62. | [Comment] Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations | Ernesto T A Marques, Rafael Dhalia | |
| 63. | [Articles] Effect of indoor residual spraying on sandfly abundance and incidence of visceral leishmaniasis in India, 2016–22: an interrupted time-series analysis and modelling study | Luc E Coffeng, Sake J de Vlas, Rudra Pratap Singh, Ananthu James, Joy Bindroo, Niteen K Sharma, Asgar Ali, Chandramani Singh, Sadhana Sharma, Michael Coleman | |
| 64. | [Articles] Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial | Paul Kim, Ana M Sanchez, Taylor J R Penke, Hannah H Tuson, James C Kime, Robert W McKee, William L Slone, Nicholas R Conley, Lana J McMillan, Cameron J Prybol, Paul M Garofolo | |
| 65. | [Personal View] The panzootic spread of highly pathogenic avian influenza H5N1 sublineage 2.3.4.4b: a critical appraisal of One Health preparedness and prevention | Marion P G Koopmans, Casey Barton Behravesh, Andrew A Cunningham, Wiku B Adisasmito, Salama Almuhairi, Pépé Bilivogui, Salome A Bukachi, Natalia Casas, Natalia Cediel Becerra, Dominique F Charron, Abhishek Chaudhary, Janice R Ciacci Zanella, Osman Dar, Nitish Debnath, Baptiste Dungu, Elmoubasher Farag, George F Gao, Margaret Khaitsa, Catherine Machalaba, John S Mackenzie, Wanda Markotter, Thomas C Mettenleiter, Serge Morand, Vyacheslav Smolenskiy, Lei Zhou, David T S Hayman, One Health High-Level Expert Panel | |
| 66. | [Comment] A model of vector-targeted interventions for visceral leishmaniasis | Christine Petersen | |
| 67. | [Review] Ebola virus disease mathematical models and epidemiological parameters: a systematic review | Rebecca K Nash, Sangeeta Bhatia, Christian Morgenstern, Patrick Doohan, David Jorgensen, Kelly McCain, Ruth McCabe, Dariya Nikitin, Alpha Forna, Gina Cuomo-Dannenburg, Joseph T Hicks, Richard J Sheppard, Tristan Naidoo, Sabine van Elsland, Cyril Geismar, Thomas Rawson, Sequoia Iris Leuba, Jack Wardle, Isobel Routledge, Keith Fraser, Pathogen Epidemiology Review Group, Natsuko Imai-Eaton, Anne Cori, H Juliette T Unwin | |
| 68. | [Correspondence] First diagnoses of Oropouche virus in Europe: how can we strengthen communication and preparedness globally? | Concetta Castilletti, Antonio Mori, Elena Pomari, Andrea Matucci, Giulia Martelli, Salvatore Curiale, Andrea Angheben, Federico Giovanni Gobbi | |
| 69. | [Comment] Edging towards a third dengue vaccine | Annika B Wilder-Smith, David O Freedman, Annelies Wilder-Smith | |
| 70. | [Articles] Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil | Mauricio L Nogueira, Monica A T Cintra, José A Moreira, Elizabeth G Patiño, Patricia Emilia Braga, Juliana C V Tenório, Lucas Bassolli de Oliveira Alves, Vanessa Infante, Daniela Haydee Ramos Silveira, Marcus Vínicius Guimarães de Lacerda, Dhelio Batista Pereira, Allex Jardim da Fonseca, Ricardo Queiroz Gurgel, Ivo Castelo-Branco Coelho, Cor Jesus Fernandes Fontes, Ernesto T A Marques, Gustavo Adolfo Sierra Romero, Mauro Martins Teixeira, André M Siqueira, Viviane Sampaio Boaventura, Fabiano Ramos, Erivaldo Elias Júnior, José Cassio de Moraes, Stephen S Whitehead, Alejandra Esteves-Jaramillo, Tulin Shekar, Jung-Jin Lee, Julieta Macey, Sabrina Gozlan Kelner, Beth-Ann G Coller, Fernanda Castro Boulos, Esper G Kallás, Phase 3 Butantan-DV Working Group | |
| 71. | [Correspondence] Tracking the spread of avian influenza A(H5N1) with alternative surveillance methods: the example of wastewater data | Francesco Branda, Massimo Ciccozzi, Fabio Scarpa | |
| 72. | [Articles] Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial | Ahmed H Fahal, Eiman Siddig Ahmed, Sahar Mubarak Bakhiet, Osama Elhadi Bakhiet, Lamis Ahmed Fahal, Abubakar Ahmed Mohamed, El Semani Widaa Mohamedelamin, Mustafa El Nour Bahar, Hadil Yassir Attalla, Emmanuel Edwar Siddig, Najwa A Mhmoud, Ahmed Mudawi Musa, Wendy W J van de Sande, Bruno Scherrer, Peelen Oyieko, Thaddaeus W Egondi, Kevin O Onyango, Katsura Hata, Wan-Yu Chu, Thomas P C Dorlo, Roger J Brüggemann, Borna A Nyaoke, Nathalie Strub-Wourgaft, Eduard E Zijlstra | |
| 73. | [Comment] Lessons learnt from conducting a randomised clinical trial in eumycetoma | Rosanne Sprute, Oliver A Cornely | |
| 74. | [Corrections] Correction to Lancet Infect Dis 2024; 24: e484 | | |
| 75. | [Articles] Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial | Isabel Leroux-Roels, Chittappen Kandiyil Prajeeth, Amare Aregay, Niranjana Nair, Guus F Rimmelzwaan, Albert D M E Osterhaus, Simone Kardinahl, Sabrina Pelz, Stephan Bauer, Valentino D'Onofrio, Azhar Alhatemi, Bart Jacobs, Fien De Boever, Sharon Porrez, Gwenn Waerlop, Carine Punt, Bart Hendriks, Ellemieke von Mauw, Sandra van de Water, Jose Harders-Westerveen, Barry Rockx, Lucien van Keulen, Jeroen Kortekaas, Geert Leroux-Roels, Paul J Wichgers Schreur | |
| 76. | [Comment] A promising boost for the Rift Valley fever vaccine pipeline | Saskia Bronder, Martina Sester | |
| 77. | [Media Watch] Living with our distant relatives | Claire Lenahan | |
| 78. | [Articles] Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial | Glenda E Gray, Kathryn Mngadi, Ludo Lavreys, Steven Nijs, Peter B Gilbert, John Hural, Ollivier Hyrien, Michal Juraska, Alex Luedtke, Philipp Mann, M Juliana McElrath, Jackline A Odhiambo, Daniel J Stieh, Janine van Duijn, Azwidihwi N Takalani, Wouter Willems, Asa Tapley, Georgia D Tomaras, Johan Van Hoof, Hanneke Schuitemaker, Edith Swann, Dan H Barouch, James G Kublin, Lawrence Corey, Maria G Pau, Susan Buchbinder, Frank Tomaka, Imbokodo/HVTN 705/HPX2008 Study Group | |
| 79. | [Comment] The need for novel approaches to HIV-1 vaccine development | Clara Lehmann, Philipp Schommers | |
| 80. | [Comment] Boosting immunity to protect from tickborne Lyme disease | Nicole Baumgarth | |
| 81. | [Articles] Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial | Santhosh Kumar Ghadge, Martina Schneider, Katrin Dubischar, Laura Wagner, Vera Kadlecek, Michaela Obersriebnig, Romana Hochreiter, Anton Klingler, Julian Larcher-Senn, Ulla Derhaschnig, Wolfgang Bender, Susanne Eder-Lingelbach, Nicole Bézay | |
| 82. | [Articles] Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study | Ming Hong Choi, Eric Yuk Fai Wan, Ian Chi Kei Wong, Esther Wai Yin Chan, Wing Ming Chu, Anthony Raymond Tam, Kwok Yung Yuen, Ivan Fan Ngai Hung | |
| 83. | [Comment] Antiviral therapy for patients with COVID-19: mix and match | Karolina Akinosoglou, Charalambos Gogos | |
| 84. | [Articles] Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65–85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial | Joseph Eiden, Carlos Fierro, Alexander White, Matthew Davis, Margaret Rhee, Mark Turner, Bryan Murray, Renee Herber, Roger Aitchison, David Marshall, Michael J Moser, Robert Belshe, Harry Greenberg, Kathleen Coelingh, Yoshihiro Kawaoka, Gabriele Neumann, Pamuk Bilsel | |
| 85. | [Comment] Bolstering influenza protection for older adults | Suryaprakash Sambhara, Paul R Knight | |
| 86. | [Grand Round] Renal transplantation using kidneys from a donor with high grade cytomegalovirus viraemia: case report and literature review | Kasra Shirini, Shani Kamberi, Cynthia Drachenberg, Abdolreza Haririan, Kapil Saharia, Raphael P H Meier | |
| 87. | [Review] The inclusion of children and adolescents in tuberculosis diagnostic development and evaluation–a consensus statement | Else M Bijker, Lyn Horn, Sylvia LaCourse, Emily L MacLean, Ben J Marais, Mark P Nicol, Laura Olbrich, James A Seddon, Jayne S Sutherland, Rinn Song, Heather J Zar, Devan Jaganath, Child TB Diagnostics Consensus Group | |
| 88. | [Personal View] Lassa fever research priorities: towards effective medical countermeasures by the end of the decade | Kristine A Moore, Julia T Ostrowsky, Angela J Mehr, Rebecca A Johnson, Angela K Ulrich, Nicolina M Moua, Petra C Fay, Peter J Hart, Josephine P Golding, Virginia Benassi, Marie-Pierre Preziosi, Ifedayo M Adetifa, George O Akpede, William K Ampofo, Danny A Asogun, Alan D T Barrett, Daniel G Bausch, Ilse de Coster, Devy M Emperador, Heinz Feldmann, Elisabeth Fichet-Calvet, Pierre B H Formenty, Robert F Garry, Donald S Grant, Stephan Günther, Swati B Gupta, Marie Jaspard, Laura T Mazzola, Sylvanus A Okogbenin, Cathy Roth, Connie S Schmaljohn, Michael T Osterholm | |
| 89. | [Articles] Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial | Heather L Platt, Christopher Bruno, Erik Buntinx, Enrique Pelayo, Diego Garcia-Huidobro, Elizabeth A Barranco-Santana, Folke Sjoberg, Joon Young Song, Carlos G Grijalva, Walter A Orenstein, Leslie Morgan, Doreen Fernsler, Weifeng Xu, Muhammad Waleed, Jianing Li, Ulrike K Buchwald, STRIDE-3 Study Group | |
| 90. | [Personal View] Measures to prevent and treat Nipah virus disease: research priorities for 2024–29 | Kristine A Moore, Angela J Mehr, Julia T Ostrowsky, Angela K Ulrich, Nicolina M Moua, Petra C Fay, Peter J Hart, Josephine P Golding, Virginia Benassi, Marie-Pierre Preziosi, Christopher C Broder, Emmie de Wit, Pierre B H Formenty, Alexander N Freiberg, Emily S Gurley, Kim Halpin, Stephen P Luby, Laura T Mazzola, Joel M Montgomery, Christina F Spiropoulou, Devendra T Mourya, Shahana Parveen, Mahmudur Rahman, Cathy Roth, Lin-Fa Wang, Michael T Osterholm | |
| 91. | [Comment] Adult pneumococcal vaccination: what are the gaps? | Claire von Mollendorf, Paul V Licciardi | |
| 92. | [Articles] Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial | Sarah E Silk, Wilmina F Kalinga, Jo Salkeld, Ivanny M Mtaka, Saumu Ahmed, Florence Milando, Ababacar Diouf, Caroline K Bundi, Neema Balige, Omar Hassan, Catherine G Mkindi, Stella Rwezaula, Thabit Athumani, Sarah Mswata, Nasoro S Lilolime, Beatus Simon, Hania Msami, Mohamed Mohamed, Damiano M David, Latipha Mohammed, Gloria Nyaulingo, Bakari Mwalimu, Omary Juma, Tunu G Mwamlima, Ibrahim A Sasamalo, Rose P Mkumbange, Janeth J Kamage, Jordan R Barrett, Lloyd D W King, Mimi M Hou, David Pulido, Cecilia Carnrot, Alison M Lawrie, Rachel E Cowan, Fay L Nugent, Rachel Roberts, Jee-Sun Cho, Carole A Long, Carolyn M Nielsen, Kazutoyo Miura, Simon J Draper, Ally I Olotu, Angela M Minassian | |
| 93. | [Articles] Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study | Oleksandr Korotych, Jay Achar, Elmira Gurbanova, Arax Hovhannesyan, Nino Lomtadze, Ana Ciobanu, Alena Skrahina, Gunta Dravniece, Liga Kuksa, Michael Rich, Naira Khachatryan, Myroslava Germanovych, Abdullat Kadyrov, Iana Terleieva, Irada Akhundova, Malik Adenov, Myahri Durdyeva, Nana Kiria, Nargiza Parpieva, Natalia Yatskevich, Rovshen Jumayev, Rustam Nurov, Saulius Diktanas, Valentina Vilc, Giovanni Battista Migliori, Askar Yedilbayev | |
| 94. | [Comment] Getting closer to an effective multi-stage malaria vaccine | Carlota Dobaño, Gemma Moncunill, Quique Bassat | |
| 95. | [Comment] Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosis | Tom Decroo, Anita Mesic, Ine Decuyper | |
| 96. | [Articles] Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial | Cissy Kityo, Ivan K Mambule, Joseph Musaazi, Simiso Sokhela, Henry Mugerwa, Gilbert Ategeka, Fiona Cresswell, Abraham Siika, Josphat Kosgei, Reena Shah, Logashvari Naidoo, Kimton Opiyo, Caroline Otike, Karlien Möller, Arvind Kaimal, Charity Wambui, Veerle Van Eygen, Perry Mohammed, Fafa Addo Boateng, Nicholas I Paton, CARES trial team | |
| 97. | [Comment] Implementing long-acting injectable cabotegravir and rilpivirine in Africa | Chloe Orkin, Kyle Ring | |
| 98. | [Articles] Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design | Jean-Michel Molina, Beatrice Bercot, Lambert Assoumou, Emma Rubenstein, Michele Algarte-Genin, Gilles Pialoux, Christine Katlama, Laure Surgers, Cécile Bébéar, Nicolas Dupin, Moussa Ouattara, Laurence Slama, Juliette Pavie, Claudine Duvivier, Benedicte Loze, Lauriane Goldwirt, Severine Gibowski, Manon Ollivier, Jade Ghosn, Dominique Costagliola, ANRS 174 DOXYVAC Study Group | |
| 99. | [Comment] Doxycycline for STIs in men who have sex with men: the next steps | Troy Grennan, Ann N Burchell | |
| 100. | [Articles] Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis | Tiana Carina Schwab, Lisa Perrig, Pauline Carlotta Göller, Freddy Fernando Guebely De la Hoz, Adrien Philippe Lahousse, Beatrice Minder, Gunar Günther, Orestis Efthimiou, Shaheed Vally Omar, Matthias Egger, Lukas Fenner | |
更新于 7 分钟前
近期历史最近 100 条记录
匿名用户只展示最新 100 条榜单历史，更多历史数据请登录后查看，支持时光机按天筛选
Sponsors
